PriceTargets.com logo

Anixa Biosciences - ANIX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 215.99%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$2.69 As of 12/20/2024 06:15 PM ET
+0 (0.00%)

This chart shows the closing price for ANIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anixa Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANIX

Analyst Price Target is $8.50
▲ +215.99% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Anixa Biosciences in the last 3 months. The average price target is $8.50, with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a 215.99% upside from the last price of $2.69.

This chart shows the closing price for ANIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Anixa Biosciences. This rating has held steady since October 2024, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
11/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
9/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
8/7/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
7/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
6/10/2024HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $7.00
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
2/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
12/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
9/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
8/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
7/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
3/23/2023HC WainwrightBoost TargetBuy$11.00 ➝ $12.00
3/22/2023Chardan CapitalReiterated RatingBuy$8.00 ➝ $9.00
2/28/2023HC WainwrightReiterated RatingBuy$11.00
12/23/2022Chardan CapitalInitiated CoverageBuy$8.00
10/4/2021HC WainwrightReiterated RatingBuy$11.00
8/31/2021HC WainwrightReiterated RatingBuy$11.00
5/21/2021HC WainwrightReiterated RatingBuy$11.00
4/19/2021HC WainwrightInitiated CoverageBuy$11.00
4/12/2021HC WainwrightInitiated CoverageBuy$11.00
2/15/2021AegisReiterated RatingBuy
6/2/2020AegisReiterated RatingBuy
3/23/2020AegisInitiated CoverageBuy$8.50
12/30/2019B. RileyLower TargetBuy$11.25 ➝ $8.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
5/25/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
7/24/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Anixa Biosciences logo
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Read More

Today's Range

Now: $2.69
Low: $2.58
High: $2.69

50 Day Range

MA: $3.19
Low: $2.53
High: $3.97

52 Week Range

Now: $2.69
Low: $2.14
High: $5.13

Volume

96,128 shs

Average Volume

108,735 shs

Market Capitalization

$86.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Anixa Biosciences?

The following Wall Street research analysts have issued stock ratings on Anixa Biosciences in the last year: D. Boral Capital, EF Hutton Acquisition Co. I, and HC Wainwright.
View the latest analyst ratings for ANIX.

What is the current price target for Anixa Biosciences?

0 Wall Street analysts have set twelve-month price targets for Anixa Biosciences in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 216.0%. D. Boral Capital has the highest price target set, predicting ANIX will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Anixa Biosciences in the next year.
View the latest price targets for ANIX.

What is the current consensus analyst rating for Anixa Biosciences?

Anixa Biosciences currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANIX will outperform the market and that investors should add to their positions of Anixa Biosciences.
View the latest ratings for ANIX.

What other companies compete with Anixa Biosciences?

Other companies that are similar to Anixa Biosciences include biote, Design Therapeutics, Voyager Therapeutics, Contineum Therapeutics and Acelyrin. Learn More about companies similar to Anixa Biosciences.

How do I contact Anixa Biosciences' investor relations team?

Anixa Biosciences' physical mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The company's listed phone number is (408) 708-9808 and its investor relations email address is [email protected]. The official website for Anixa Biosciences is www.anixa.com. Learn More about contacing Anixa Biosciences investor relations.